Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada.
Loading...
Authors
Andrews, Robert
Issue Date
2025-03-26
Type
Journal Article
Randomized Controlled Trial
Multicenter Study
Randomized Controlled Trial
Multicenter Study
Language
en
Keywords
Diabetes Mellitus, Type 2 , Digital Technology , Exercise , Feasibility Studies , Telemedicine , eHealth
Alternative Title
Abstract
Objectives Assess the feasibility of a mobile health (mHealth)-supported home-delivered physical activity (PA) intervention (MOTIVATE-T2D) in people with recently diagnosed type 2 diabetes (T2D).
Design Feasibility multicentre, parallel group, randomised controlled trial (RCT).
Setting Participants were recruited from England and Canada using a decentralised design.
Participants Adults (40–75 years) recently diagnosed with T2D (5–24 months).
Interventions Participants were randomised 1:1 to intervention (MOTIVATE-T2D) or active control groups. Participants codesigned 6month- home-delivered, personalised, progressive PA programmes supported by virtual behavioural counselling. MOTIVATE-T2D used biofeedback from wearable technologies to support the programme. The active control group received the same intervention without wearables.
Outcomes The primary outcomes were recruitment rate, retention and adherence to purposeful exercise. Clinical data on effectiveness were collected as exploratory outcomes at baseline, 6 and 12 months, with HbA1c and systolic blood pressure (BP) proposed as primary outcomes for a future full RCT.
Results n=135 eligible participants expressed an interest in the trial, resulting in 125 participants randomised (age 55±9 years, 48% female, 81% white), a recruitment rate of 93%. Retention at 12 months was 82%. MOTIVATE-T2D participants were more likely to start (OR 10.4, CI 3.4 to 32.1) and maintain purposeful exercise at 6 (OR 7.1, CI 3.2 to 15.7) and 12 months (OR 2.9, CI 1.2 to 7.4). Exploratory clinical outcomes showed a potential effect in favour of MOTIVATE-T2D, including proposed primary outcomes HbA1c and systolic BP (between-group mean differences: HbA1c: 6 months: −5% change from baseline, CI −10 to 2: 12 months: −2% change from baseline, CI −8 to −4; systolic BP: 6 months: −1 mm Hg, CI −5 to 3: 12 months: −4 mm Hg, CI −8 to 1).
Conclusions Our findings support the feasibility of delivering the MOTIVATE-T2D mHealth-supported PA intervention for people with recently diagnosed T2D and progression to a full RCT to examine its clinical and cost-effectiveness.
Trial registration number ISRCTN: 14335124; ClinicalTrials.gov: NCT0465353.
Description
© Author(s) (or their
employer(s)) 2025. Re-use
permitted under CC BY.
Published by BMJ Group
Citation
Hesketh K, Low J, Andrews R, Blitz S, Buckley B, Falkenhain K, Job J, Jones CA, Jones H, Jung ME, Little J, Mateus C, Percival SL, Pulsford R, Russon CL, Singer J, Sprung VS, McManus AM, Cocks M. Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada. BMJ Open. 2025 Mar 26;15(3):e092260. doi: 10.1136/bmjopen-2024-092260. PMID: 40139900.
Publisher
BMJ Open
License
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.
Journal
BMJ open
Volume
15
Issue
3
PubMed ID
ISSN
2044-6055